On July 23, 2025, Windtree Therapeutics entered a Common Stock Purchase Agreement allowing for the sale of up to $500 million in shares over 36 months, as well as issuing a $10 million convertible promissory note to the investor. This agreement requires regulatory approvals to commence sales.